8-K: MAIA Biotechnology Completes Enrollment in Phase 2 Lung Cancer Trial, Topline Data Expected in Second Half of 2024

MAIA Biotechnology has completed enrollment in its Phase 2 clinical trial for THIO-101 in non-small cell lung cancer, with topline data anticipated in the second half of 2024.

Summary

• MAIA Biotechnology has finished enrolling patients in its Phase 2 THIO-101 clinical trial for non-small cell lung cancer.
• The trial reached its target of 41 patients at the 180mg dose on February 19, 2024.
• A total of 79 patients have received the drug at various doses: 24 at 60mg, 41 at 180mg, and 14 at 360mg.
• The trial was originally designed to include up to 182 patients across three dose levels.
• Following the selection of 180mg as the optimal dose in December 2023, all subsequent patients were enrolled at this dose.
• The company expects to release topline data from the trial in the second half of 2024.
• THIO-101 is being developed as a second or later line treatment for NSCLC patients who have progressed after initial checkpoint inhibitor therapy.
• The trial is evaluating the safety, tolerability, and preliminary efficacy of THIO followed by the checkpoint inhibitor cemiplimab.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of enrollment ahead of schedule and promising preliminary data. The company's confidence in the potential of THIO-101 is evident, although the inherent risks of clinical trials are acknowledged.

Positives

• Enrollment in the Phase 2 trial was completed ahead of schedule.
• The selection of the optimal dose was completed in December 2023.
• Preliminary data suggests unprecedented rates of disease control and response.
• THIO-101 is the first completed clinical study of a telomere targeting agent in cancer drug development.
• The trial is evaluating THIO followed by the checkpoint inhibitor cemiplimab.

Risks

• The company acknowledges that forward-looking statements are subject to risks and uncertainties.
• The actual results of the clinical trial may differ materially from expectations.
• There are risks associated with the development, manufacturing, and commercialization of the product candidate.
• The company's ability to obtain and maintain intellectual property protection is also a risk.

Future Outlook

The company anticipates releasing topline data from the THIO-101 Phase 2 clinical trial in the second half of 2024.

Management Comments

• Vlad Vitoc, M.D., MAIA's Chairman and Chief Executive Officer, stated that enrollment in the Phase 2 THIO-101 trial has been strong from the start.
• Vlad Vitoc also mentioned that preliminary data has demonstrated unprecedented rates of disease control and response to date.

Industry Context

The completion of enrollment in the THIO-101 trial is a significant milestone in the development of telomere-targeting agents for cancer treatment, an area of growing interest in the immuno-oncology field. The trial's focus on NSCLC, a common and challenging cancer, aligns with the industry's efforts to improve outcomes for patients with advanced disease.

Comparison to Industry Standards

• The trial is evaluating THIO in combination with cemiplimab, a checkpoint inhibitor, which is a common approach in NSCLC treatment.
• The use of telomere-targeting agents is a novel approach, and THIO-101 is the first completed clinical study of such an agent.
• The trial's design, which includes a dose-finding phase and evaluation of overall response rate, is consistent with industry standards for Phase 2 clinical trials.
• Other companies such as Bristol Myers Squibb with Opdivo and Merck with Keytruda are also developing checkpoint inhibitors for NSCLC, but MAIA's approach with a telomere targeting agent is unique.

Stakeholder Impact

• Shareholders may react positively to the news of completed enrollment and promising preliminary data.
• Patients with NSCLC may benefit from the development of a new treatment option.
• The company's employees are likely to be motivated by the progress of the clinical trial.

Next Steps

• The company will continue to monitor the enrolled patients.
• Topline data from the trial is expected in the second half of 2024.

Key Dates

Keywords

THIO-101, Non-Small Cell Lung Cancer, NSCLC, Telomere Targeting Agent, Clinical Trial, Immunotherapy, Cemiplimab, Checkpoint Inhibitor, Cancer Treatment, MAIA Biotechnology